- Raised $16M funding round led by Grove Ventures, Mar 2026
- Raised $5.5M funding round led by TLV Partners, Mar 2022
About
Scala Biodesign develops cutting-edge computational protein design solutions to address complex protein development challenges in the pharmaceutical, chemical, diagnostics and food sectors. Antibodies, vaccines and sustainable chemical manufacturing demand proteins that meet exceptionally stringent requirements in activity, shelf-life and safety. Yet, traditional methods for protein engineering are costly, lengthy and failure-prone. Scala’s one-shot approach dramatically accelerates the development process, increases success rates and slashes R&D efforts, thereby enabling its partners to pursue challenging projects that were previously beyond their reach. Scala has partnered with some of the largest pharma and chemical corporations worldwide and its technology has successfully overcome development challenges that confounded expert teams for years.
Scala, under the leadership of Dr. Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO), leverages the technologies they developed in the group of Prof. Sarel Fleishman (Chief Scientist) which was licensed from the Weizmann Institute of Science. Scala is positioned to become the primary destination for corporations venturing into new protein-based product development.
Funding history · 2 rounds · $21.5M total
Q&A
- What is Scala Biodesign's primary focus?
- Scala Biodesign specializes in computational protein design, developing solutions for complex protein development challenges in the pharmaceutical, chemical, diagnostics, and food sectors.
- When was Scala Biodesign founded?
- Scala Biodesign was founded in March 2022.
- What is Scala Biodesign's current employee count?
- Scala Biodesign has 11-50 employees.
- Who are the key leaders at Scala Biodesign?
- Scala Biodesign is led by Dr. Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO), with Prof. Sarel Fleishman serving as Chief Scientist.
- What was Scala Biodesign's initial funding round?
- In March 2022, Scala Biodesign raised $5,500,000 in a funding round led by.
- What was Scala Biodesign's most recent funding round?
- In March 2026, Scala Biodesign raised $16,000,000 in a funding round led by.
- What is the total amount of funding Scala Biodesign has raised to date?
- Scala Biodesign has raised a total of $21,500,000.
- From where did Scala Biodesign license its core technology?
- Scala Biodesign licensed its core technologies from the Weizmann Institute of Science, developed in the group of Prof. Sarel Fleishman.
- In which sectors does Scala Biodesign operate?
- Scala Biodesign operates in the Health Tech & Life Sciences, Pharma & Medical Biotechnology, and Drugs Discovery & Development sectors.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | scala-bio.com/ |
|---|---|
| linkedin.com/company/90994251 |
Identifiers & details
| Founded | 2022-3 |
|---|---|
| Employees (exact) | 22 |
Radar intelligence
Web history (Wayback)
| Domain | scala-bio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|